Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease

NCT06175468 | Unknown Phase 3

• 1 other identifier: CMUH112-REC2-154
• Study Type: interventional
• Target: 170
• Locations: 1 country
• Sites: 1

Brief Summary

"Formosa 1-Breath Free (NRICM101) " has been widely known in Taiwan to treat COVID-19. However, there is no phase III pivotal clinical trial of "Formosa 1-Breath Free (NRICM101) " . In order to obtain scientific, standardized, and comparable clinical results, the study will be implemented to evaluate the efficacy of safety of "Formosa 1-Breath Free (NRICM101) ". The objective of the study was used the product which be provided by Tian-I Pharmaceutical Co. Ltd. to evaluate the efficacy and safety of the subjects with the symptoms of COVID-19 or Influenza-like after taking "Formosa 1-Breath Free (NRICM101) ". This study is a randomized, double-blind, parallel controlled clinical trial. The study consisted of 3 cycles: screening period, treatment period (5 days) and follow-up period. The treatment of this study is divided into two groups: The test drug is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day；The control drug is the placebo (dummy) 5g/bag, 3 times a day. The sample size in the study is at least 150 people who can be evaluated, and the dropout rate of the test is 10-15%. The estimated sample size is around 170 people. After signing the ICF, vital signs (sitting blood pressure, pulse rate, SpO2, respiratory rate and body temperature), physical examination, chest X-ray, and laboratory test will be checked in screening period. Only subjects with clinically acceptable and following the inclusion and exclusion criteria will eligible to enroll in this study. Compliance will be assured by administration of the study drug under the supervision of the investigator or his deputy. Subjects will be free to withdraw at any time without stating any reason. Data will be analyzed from those subjects who complete the entire study; however, the case report forms and the final study report should include reasons for withdrawals and any necessary treatment.

Conditions

Influenza Viral Infections; COVID-19

Keywords

Formosa 1-Breath Free (NRICM101); COVID-19; Influenza

Outcome Measures

Primary Outcomes (1)

• Sore Throat Visual Analogue Scale (VAS)

  Assessing the improvement in sore throat in subjects with symptoms of COVID-19 or influenza-like symptoms. Using the Visual Analogue Scale (VAS) with a range of 0-100, the absolute value of the baseline change in pain intensity is calculated as the Sum of Pain Intensity Differences (SPID), serving as an indicator of the degree of therapeutic improvement.

  Sore throat will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

Secondary Outcomes (6)

• Cough Cough Symptom Score (CSS)

  Cough will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

• Fatigue Visual Analogue Scale (VAS)

  Fatigue will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

• Nasal Symptoms Total Nasal Symptom Score (TNSS)

  Nasal symptoms will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

• Fever Level

  Fever measurements will be taken before the first dose, and one hour after each dose for 5 days

• Safety evaluation

  Record the adverse event form the baseline to the end of study and follow up to 14 days

Study Arms (2)

Placebo control group

PLACEBO COMPARATOR

take the placebo drug 5g/bag、three times a day, treatment for 5 days

Drug: Placebo control drug

Treatment group

ACTIVE COMPARATOR

take the Formosa 1-Breath Free (NRICM101) 5g/bag、three times a day, treatment for 5 days

Drug: Formosa 1-Breath Free (NRICM101)

Interventions

Formosa 1-Breath Free (NRICM101) DRUG

After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.

Treatment group

Placebo control drug DRUG

After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.

Placebo control group

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects who meet the criteria guideline in the "Seasonal Influenza Prevention and Control Manual" recommended by the Taiwan Centers for Disease Control, or are determined by the investigator to have mild symptoms of COVID-19, including fever, sore throat, cough, and fatigue.
• Subjects who have had a fever (body temperature ≥37.5°C and ≤39°C) before their initial dose.
• Throat pain intensity score \>30 points during the screening period.
• Cough severity score \>3 points during the screening period.
• Fatigue level score \>30 points during the screening period.
• Able to perform activities of daily living and aged 20 weeks or older.
• Duration of illness ≤24 hours.
• Obtained informed consent from the subject and signed the informed consent form.

You may not qualify if:

• Subject has used other medications for this condition (including cold medicine, antibiotics, antiviral drugs, and similar traditional Chinese medicines) within the 24 hours prior to screening, or is determined by the investigator to require the use of antibiotics or COVID-19 anti-virus drugs.
• Subject has used corticosteroids or NSAIDs for an extended period within the four weeks prior to screening.
• Subject has had poorly controlled chronic diseases in the past five years, including cardiovascular, respiratory, gastrointestinal, immune-related conditions, or mental health disorders (as determined by the investigator).
• Subject has had chronic bronchitis, streptococcal pharyngitis, herpetic pharyngitis, or pneumonia within the past two years or at the time of screening (as determined by the investigator).
• Subject is allergic to the investigational drug or its components.
• Women who are pregnant, breastfeeding, or planning to become pregnant.
• Subject has participated in other drug clinical trials within the 90 days prior to screening.

Sponsors & Collaborators

• China Medical University Hospital: lead
• Tian-I Pharmaceutical,. Co. Ltd.: collaborator
• China Medical University, China: collaborator
• Qualitix Clinical Research Co., Ltd.: collaborator

Study Sites (1)

China Medical University Hospital

Taichung, Taiwan

Location

MeSH Terms

Conditions

COVID-19; Influenza, Human

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Orthomyxoviridae Infections

Study Officials

• Chia-Ing Li, PhD

  Associate Professor

  STUDY CHAIR

Central Study Contacts

Chia-Ing Li, PhD

CONTACT

+ 886-4-22052121; 006446@tool.caaumed.org.tw

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 13, 2023
• First Posted: December 19, 2023
• Study Start: December 15, 2023
• Primary Completion: April 1, 2024
• Study Completion: August 1, 2024
• Last Updated: December 19, 2023

Record last verified: 2023-12

Locations

TW (1)